Table 2. Overall survival and disease free survival according to the ENO1 rs2274971A > G, PFKM rs11168417C > T, PFKP rs1132173C > T, and PDK2 rs3785921G > A genotypes.
| Polymorphism/genotype | No. of Cases (%)a | Overall survival |
Disease free survival |
||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of deaths (%)b | 5Y-OSR (%)c | HR (95% CI)d | Pd | No. of Event (%)b | 5Y-DFSR (%)c | HR (95% CI)d | Pd | ||
| ENO1 rs2274971e | |||||||||
| AA | 448 (59.1) | 128 (28.6) | 58 | 1.00 | 205 (45.8) | 41 | 1.00 | ||
| AG | 266 (35.1) | 63 (23.7) | 67 | 0.73 (0.54–1.00) | 0.05 | 105 (39.5) | 50 | 0.73 (0.58–0.93) | 0.01 |
| GG | 44 (5.8) | 8 (18.2) | 76 | 0.55 (0.27–1.12) | 0.10 | 15 (34.10 | 59 | 0.69 (0.41–1.17) | 0.17 |
| Dominant | 310 (40.9) | 71 (22.9) | 68 | 0.70 (0.52–0.95) | 0.02 | 120 (38.7) | 51 | 0.73 (0.58–0.92) | 7 × 10−3 |
| Recessive | 714 (94.2) | 191 (26.8) | 61 | 0.61 (0.30–1.24) | 0.17 | 310 (43.4) | 44 | 0.78 (0.46–1.31) | 0.34 |
| Codominant | 0.73 (0.57–0.94) | 0.02 | 0.77 (0.64–0.94) | 0.01 | |||||
| PFKM rs11168417e | |||||||||
| CC | 471 (61.1) | 109 (23.1) | 67 | 1.00 | 186 (39.5) | 49 | 1.00 | ||
| CT | 264 (34.2) | 88 (33.3) | 53 | 1.49 (1.11–1.99) | 8 × 10−3 | 132 (50.0) | 40 | 1.28 (1.02–1.61) | 0.04 |
| TT | 36 (4.7) | 8 (22.2) | 62 | 1.11 (0.54–2.29) | 0.78 | 14 (38.9) | 38 | 1.03 (0.59–1.77) | 0.93 |
| Dominant | 300 ((38.9) | 96 (32.0) | 54 | 1.44 (1.09–1.91) | 0.01 | 146 (48.7) | 39 | 1.25 (1.00–1.56) | 0.05 |
| Recessive | 735 (95.3) | 197 (26.8) | 62 | 0.95 (0.47–1.93) | 0.89 | 318 (43.3) | 46 | 0.94 (0.55–1.60) | 0.81 |
| Codominant | 1.28 (1.02–1.61) | 0.04 | 1.15 (0.96–1.38) | 0.13 | |||||
| PFKP rs1132173e | |||||||||
| CC | 207 (26.9) | 57 (27.5) | 65 | 1.00 | 90 (43.5) | 46 | 1.00 | ||
| CT | 401 (52.1) | 113 (28.2) | 57 | 1.06 (0.76–1.48) | 0.72 | 184 (45.9) | 41 | 1.09 (0.84–1.42) | 0.50 |
| TT | 162 (21.0) | 32 (19.8) | 73 | 0.83 (0.53–1.29) | 0.41 | 57 (35.2) | 55 | 0.77 (0.55–1.08) | 0.14 |
| Dominant | 563 (73.1) | 145 (25.8) | 62 | 1.00 (0.73–1.37) | 0.99 | 241 (42.8) | 45 | 0.99 (0.78–1.27) | 0.96 |
| Recessive | 608 (79.0) | 170 (28.0) | 60 | 0.80 (0.54–1.17) | 0.25 | 274 (45.1) | 43 | 0.73 (0.55–0.98) | 0.03 |
| Codominant | 0.93 (0.76–1.15) | 0.49 | 0.90 (0.77–1.06) | 0.20 | |||||
| PDK2 rs3785921e | |||||||||
| GG | 342 (44.3) | 85 (24.9) | 64 | 1.00 | 133 (38.9) | 49 | 1.00 | ||
| GA | 356 (46.1) | 95 (26.7) | 62 | 1.31 (0.97–1.76) | 0.08 | 163 (45.8) | 42 | 1.39 (1.10–1.76) | 5 × 10−3 |
| AA | 74 (9.6) | 23 (31.1) | 59 | 1.34 (0.82–2.17) | 0.24 | 36 (48.7) | 40 | 1.44 (0.98–2.11) | 0.06 |
| Dominant | 430 (55.7) | 118 (27.4) | 62 | 1.31 (0.99–1.75) | 0.06 | 199 (46.3) | 42 | 1.40 (1.12–1.75) | 3 × 10−3 |
| Recessive | 698 (90.4) | 180 (25.8) | 63 | 1.17 (0.74–1.85) | 0.50 | 296 (42.4) | 46 | 1.22 (0.85–1.74) | 0.29 |
| Codominant | 1.20 (0.98–1.49) | 0.08 | 1.26 (1.07–1.49) | 6 × 10−3 | |||||
Abbreviations: 5Y-OSR, five year-overall survival rate; 5Y-DFSR, five year-disease free survival rate; HR, hazard ratio; CI, confidence interval.
aColumn percentage.
bRow percentage.
cFive year-overall survival rate and five year-disease free survival rate, proportion of survival derived from Kaplan-Meier analysis.
dHRs, 95% CIs, and their corresponding P values were calculated using multivariate Cox proportional hazard models, adjusted for age, gender, smoking status, diabetes, tumor histology, pathologic stage, adjuvant therapy, and body mass index.
eGenotype failures: 24 case for rs2274971, 11 case for rs11168417, 12 case for rs1132173, and 10 case for rs3785921.